A Phase 4 interventional study of cyclosporine A 0.05% eye drops in Outcomes of Cyclosporine Eye Drops in Herpetic Keratitis, sponsored by Farwaniya Hospital. Completed at 1 site in Kuwait. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2024-08-07.
Sponsored by Farwaniya Hospital · Phase 4, Interventional, and Treatment
Objective: To compare the additive effect of topical cyclosporine A 0.05% eye drops to prednisolone eye drops, with topical prednisolone acetate 1% eye drops alone in treatment of herpetic stromal keratitis.
Methods: Patients diagnosed with herpetic stromal keratitis are randomly divided into 2 groups; Group A: receive cyclosporine eye drops together with prednisolone eye drops.
Group B: receive topical prednisolone with placebo eye drops (tear replacement).
The 2 groups receive systemic acyclovir therapeutic dose 400 mg five times daily, which then tapered to twice daily prophylactic dose after one month of treatment. Follow up for patients is scheduled as a weekly visit for a duration of 2 months.
108 studies on the registry are indexed under Keratitis; 19 are open to participants now.
This study's enrollment of 30 is below the median of 40 across 70 interventional studies indexed under Keratitis.
Browse Keratitis studies →Farwaniya Hospital is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
receive cyclosporine eye drops together with prednisolone eye drops.
Drug: cyclosporine A 0.05% eye drops
receive topical prednisolone with placebo eye drops (tear replacement).
Drug: cyclosporine A 0.05% eye drops
Patients diagnosed with herpetic stromal keratitis are randomly divided into 2 groups; Group A: receive cyclosporine eye drops together with prednisolone eye drops. Group B: receive topical prednisolone with placebo eye drops (tear replacement). The 2 groups receive systemic acyclovir therapeutic dose 400 mg five times daily, which then tapered to twice daily prophylactic dose after one month of treatment. Follow up for patients is scheduled as a weekly visit for a duration of 2 months.
duration of ttt
duration of treatment until complete resolving of keratitis
Time frame: 3 months
improvement in visual acuity
by snellen chart
Time frame: 3 months
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cyclosporine
Farwaniya Hospital